Status:
UNKNOWN
Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)
Lead Sponsor:
Columbia Northwest Pharmaceuticals
Conditions:
Post-Traumatic Stress Disorder
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.
Detailed Description
This initial proof of concept trial design is intended to explore multiple variables. Fist, it is intended to determine if carvedilol has any statistically significant effect over placebo on the vario...
Eligibility Criteria
Inclusion
- Diagnosis of Post Traumatic Stress Disorder according to DSM-IV
- Must be able to speak, read and understand the English language and be able to provide written informed consent
Exclusion
- current, unstable and significant medical condition/illness
- bronchial asthma or related bronchospastic condition
- AV block
- Sick Sinus Syndrome
- Bradycardia
- Peripheral hear disease
- Unstable thyroid disorder
- History of seizure disorder
- Females who are pregnant, lactating or planning to become pregnant
- Bipolar
- Schizophrenia
- Dementia
- Intolerance or hypersensitivity to alpha or beta blockers
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01221792
Start Date
October 1 2010
End Date
August 1 2011
Last Update
June 8 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Artemis Institute for Clinical Research
San Diego, California, United States, 92123
2
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States, 70601
3
Northwest Clinical Research Center
Bellevue, Washington, United States, 98007